Paeoniflorin Sensitizes Breast Cancer Cells to Tamoxifen by Downregulating microRNA-15b via the FOXO1/CCND1/β-Catenin Axis

References

• DeSantisCE, MaJ, GaudetMM, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69(6):438–451. doi:10.3322/caac.2158331577379
   PubMed Web of Science ®Google Scholar
• OsborneCK, SchiffR. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62(1):233–247. doi:10.1146/annurev-med-070909-18291720887199
   PubMed Web of Science ®Google Scholar
• JordanVC. Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer. Endocr Relat Cancer. 2014;21(3):R235–246. doi:10.1530/ERC-14-009224659478
   PubMed Web of Science ®Google Scholar
• JagerNG, LinnSC, SchellensJH, BeijnenJH. Tailored tamoxifen treatment for breast cancer patients: a perspective. Clin Breast Cancer. 2015;15(4):241–244. doi:10.1016/j.clbc.2015.04.00525997856
   PubMed Web of Science ®Google Scholar
• XingJ, LiJ, FuL, GaiJ, GuanJ, LiQ. SIRT4 enhances the sensitivity of ER-positive breast cancer to tamoxifen by inhibiting the IL-6/STAT3 signal pathway. Cancer Med. 2019;8(16):7086–7097. doi:10.1002/cam4.255731573734
   PubMed Web of Science ®Google Scholar
• ZhouYX, GongXH, ZhangH, PengC. A review on the pharmacokinetics of paeoniflorin and its anti-inflammatory and immunomodulatory effects. Biomed Pharmacother. 2020;130:110505. doi:10.1016/j.biopha.2020.11050532682112
   PubMed Web of Science ®Google Scholar
• FangS, ZhuW, ZhangY, ShuY, LiuP. Paeoniflorin modulates multidrug resistance of a human gastric cancer cell line via the inhibition of NF-kappaB activation. Mol Med Rep. 2012;5(2):351–356. doi:10.3892/mmr.2011.65222051979
   PubMed Web of Science ®Google Scholar
• ZhangL, WeiW. Anti-inflammatory and immunoregulatory effects of paeoniflorin and total glucosides of paeony. Pharmacol Ther. 2020;207:107452. doi:10.1016/j.pharmthera.2019.10745231836457
   PubMed Web of Science ®Google Scholar
• ChenY, ZhangR, ZhaoW, et al. Paeoniflorin exhibits antitumor effects in nasopharyngeal carcinoma cells through downregulation of NEDD4. Am J Transl Res. 2019;11(12):7579–7590.31934302
   PubMed Web of Science ®Google Scholar
• GaoJ, SongL, XiaH, PengL, WenZ. 6ʹ-O-galloylpaeoniflorin regulates proliferation and metastasis of non-small cell lung cancer through AMPK/miR-299-5p/ATF2 axis. Respir Res. 2020;21(1):39. doi:10.1186/s12931-020-1277-632014006
   PubMed Web of Science ®Google Scholar
• ZhouZ, WangS, SongC, HuZ. Paeoniflorin prevents hypoxia-induced epithelial-mesenchymal transition in human breast cancer cells. Onco Targets Ther. 2016;9:2511–2518. doi:10.2147/OTT.S10242227175085
   PubMed Web of Science ®Google Scholar
• WangS, LiuW. Paeoniflorin inhibits proliferation and promotes apoptosis of multiple myeloma cells via its effects on microRNA29b and matrix metalloproteinase2. Mol Med Rep. 2016;14(3):2143–2149. doi:10.3892/mmr.2016.549827430753
   PubMed Web of Science ®Google Scholar
• QiLQ, SunB, YangBB, LuS. MiR-15b facilitates breast cancer progression via repressing tumor suppressor PAQR3. Eur Rev Med Pharmacol Sci. 2020;24(2):740–748. doi:10.26355/eurrev_202001_2005432016977
   PubMed Web of Science ®Google Scholar
• ZhaoZ, ZhangL, YaoQ, TaoZ. miR-15b regulates cisplatin resistance and metastasis by targeting PEBP4 in human lung adenocarcinoma cells. Cancer Gene Ther. 2015;22(3):108–114. doi:10.1038/cgt.2014.7325721211
   PubMed Web of Science ®Google Scholar
• Guney EskilerG, CecenerG, TuncaB, EgeliU. An in vitro model for the development of acquired tamoxifen resistance. Cell Biol Toxicol. 2016;32(6):563–581. doi:10.1007/s10565-016-9355-827585693
   PubMed Web of Science ®Google Scholar
• WangL, ZhangX, WangZY. The Wilms’ tumor suppressor WT1 regulates expression of members of the epidermal growth factor receptor (EGFR) and estrogen receptor in acquired tamoxifen resistance. Anticancer Res. 2010;30(9):3637–3642.20944147
   PubMed Web of Science ®Google Scholar
• ClarkeR, TysonJJ, DixonJM. Endocrine resistance in breast cancer – an overview and update. Mol Cell Endocrinol. 2015;418(Pt 3):220–234. doi:10.1016/j.mce.2015.09.03526455641
   PubMed Web of Science ®Google Scholar
• DroogM, BeelenK, LinnS, ZwartW. Tamoxifen resistance: from bench to bedside. Eur J Pharmacol. 2013;717(1–3):47–57. doi:10.1016/j.ejphar.2012.11.07123545365
   PubMed Web of Science ®Google Scholar
• LiG, ZhangJ, XuZ, LiZ. ERalpha36 as a potential therapeutic target for tamoxifen-resistant breast cancer cell line through EGFR/ERK signaling pathway. Cancer Manag Res. 2020;12:265–275. doi:10.2147/CMAR.S22641032021441
   PubMed Web of Science ®Google Scholar
• XiangY, ZhangQ, WeiS, HuangC, LiZ, GaoY. Paeoniflorin: a monoterpene glycoside from plants of Paeoniaceae family with diverse anticancer activities. J Pharm Pharmacol. 2020;72(4):483–495. doi:10.1111/jphp.1320431858611
   PubMed Web of Science ®Google Scholar
• ZhangJ, YuK, HanX, et al. Paeoniflorin influences breast cancer cell proliferation and invasion via inhibition of the notch1 signaling pathway. Mol Med Rep. 2018;17(1):1321–1325. doi:10.3892/mmr.2017.800229115554
   PubMed Web of Science ®Google Scholar
• ZhangQ, YuanY, CuiJ, XiaoT, JiangD. Paeoniflorin inhibits proliferation and invasion of breast cancer cells through suppressing notch-1 signaling pathway. Biomed Pharmacother. 2016;78:197–203. doi:10.1016/j.biopha.2016.01.01926898442
   PubMed Web of Science ®Google Scholar
• ZhengYB, XiaoGC, TongSL, et al. Paeoniflorin inhibits human gastric carcinoma cell proliferation through up-regulation of microRNA-124 and suppression of PI3K/Akt and STAT3 signaling. World J Gastroenterol. 2015;21(23):7197–7207. doi:10.3748/wjg.v21.i23.719726109806
   PubMed Web of Science ®Google Scholar
• MiaoS, WangJ, XuanL, LiuX. LncRNA TTN-AS1 acts as sponge for miR-15b-5p to regulate FBXW7 expression in ovarian cancer. Biofactors. 2020;46(4):600–607. doi:10.1002/biof.162232049388
   PubMed Web of Science ®Google Scholar
• WeiS, PengL, YangJ, et al. Exosomal transfer of miR-15b-3p enhances tumorigenesis and malignant transformation through the DYNLT1/Caspase-3/Caspase-9 signaling pathway in gastric cancer. J Exp Clin Cancer Res. 2020;39(1):32. doi:10.1186/s13046-019-1511-632039741
   PubMed Web of Science ®Google Scholar
• LuL, LiY, WenH, FengC. Overexpression of miR-15b promotes resistance to sunitinib in renal cell carcinoma. J Cancer. 2019;10(15):3389–3396. doi:10.7150/jca.3167631293642
   PubMed Web of Science ®Google Scholar
• KedmiM, Ben-ChetritN, KornerC, et al. EGF induces microRNAs that target suppressors of cell migration: miR-15b targets MTSS1 in breast cancer. Sci Signal. 2015;8(368):ra29. doi:10.1126/scisignal.200586625783158
   PubMed Web of Science ®Google Scholar
• Grinan-LisonC, Olivares-UrbanoMA, JimenezG, et al. miRNAs as radio-response biomarkers for breast cancer stem cells. Mol Oncol. 2020;14(3):556–570. doi:10.1002/1878-0261.1263531930680
   PubMed Web of Science ®Google Scholar
• ZouY, LinX, BuJ, et al. Timeless-stimulated miR-5188-FOXO1/beta-catenin-c-jun feedback loop promotes stemness via ubiquitination of beta-catenin in breast cancer. Mol Ther. 2020;28(1):313–327. doi:10.1016/j.ymthe.2019.08.01531604679
   PubMed Web of Science ®Google Scholar
• ShiF, LiT, LiuZ, et al. FOXO1: another avenue for treating digestive malignancy? Semin Cancer Biol. 2018;50:124–131. doi:10.1016/j.semcancer.2017.09.00928965871
   PubMed Web of Science ®Google Scholar
• ZhaoM, LuoR, LiuY, et al. miR-3188 regulates nasopharyngeal carcinoma proliferation and chemosensitivity through a FOXO1-modulated positive feedback loop with mTOR-p-PI3K/AKT-c-JUN. Nat Commun. 2016;7(1):11309. doi:10.1038/ncomms1130927095304
   PubMed Web of Science ®Google Scholar
• YuJM, SunW, WangZH, et al. TRIB3 supports breast cancer stemness by suppressing FOXO1 degradation and enhancing SOX2 transcription. Nat Commun. 2019;10(1):5720. doi:10.1038/s41467-019-13700-631844113
   PubMed Web of Science ®Google Scholar
• AiB, KongX, WangX, et al. LINC01355 suppresses breast cancer growth through FOXO3-mediated transcriptional repression of CCND1. Cell Death Dis. 2019;10(7):502. doi:10.1038/s41419-019-1741-831243265
   PubMed Web of Science ®Google Scholar
• ZhangD, DaiD, ZhouM, et al. Inhibition of cyclin D1 expression in human glioblastoma cells is associated with increased temozolomide chemosensitivity. Cell Physiol Biochem. 2018;51(6):2496–2508. doi:10.1159/00049592030562739
   PubMedGoogle Scholar
• VarmaK, ChauhanA, BhargavaM, MisraV, SrivastavaS. Association of different patterns of expression of beta-catenin and cyclin D1 with pathogenesis of breast carcinoma. Indian J Pathol Microbiol. 2020;63(1):13–18. doi:10.4103/IJPM.IJPM_419_1932031116
   PubMed Web of Science ®Google Scholar
• FatimaI, El-AyachiI, PlayaHC, et al. Simultaneous multi-organ metastases from chemo-resistant triple-negative breast cancer are prevented by interfering with WNT-signaling. Cancers (Basel. 2019;11(12):12. doi:10.3390/cancers11122039
   Web of Science ®Google Scholar
• FuY, WangZ, LuoC, et al. Downregulation of CXXC finger protein 4 leads to a tamoxifen-resistant phenotype in breast cancer cells through activation of the Wnt/beta-catenin pathway. Transl Oncol. 2020;13(2):423–440. doi:10.1016/j.tranon.2019.12.00531911277
   PubMed Web of Science ®Google Scholar
• XiaX, XiaJ, YangH, et al. Baicalein blocked cervical carcinoma cell proliferation by targeting CCND1 via Wnt/beta-catenin signaling pathway. Artif Cells Nanomed Biotechnol. 2019;47(1):2729–2736. doi:10.1080/21691401.2019.163605531284780
   PubMed Web of Science ®Google Scholar